Quick Answer
Monopar Therapeutics reported R&D Expense of $9.90 million for fiscal year 2025.
Monopar Therapeutics R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.90M | -23.8% |
| 2024 | $13.01M | +132.2% |
| 2023 | $5.60M | -26.2% |
| 2022 | $7.59M | +16.9% |
| 2021 | $6.49M | +59.7% |
| 2020 | $4.07M | +106.5% |
| 2019 | $1.97M | +10.9% |
| 2018 | $1.77M | +89.7% |
| 2017 | $935.3K | +233.6% |
| 2016 | $280.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.59M | +163.1% | +49.7% |
| June 30, 2025 | $1.73M | +53.0% | +5.3% |
| March 31, 2025 | $1.64M | +70.1% | +67.0% |
| September 30, 2024 | $984.3K | -25.2% | -13.0% |
| June 30, 2024 | $1.13M | -29.1% | +17.1% |
| March 31, 2024 | $966.1K | -41.6% | -26.6% |
| September 30, 2023 | $1.32M | -24.0% | -17.4% |
| June 30, 2023 | $1.59M | -23.3% | -3.5% |
- Monopar Therapeutics showed a decrease of -23.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Monopar Therapeutics’s r&d expense has grown by 3432.7% (from $280.4 thousand to $9.90 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: